Hepion Pharmaceuticals, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Wijngaard Peter | — | Purchase | 2,500 | $3.09 | $7,725 | 7,001 | Nov 27, 2023 |
| Wijngaard Peter | — | Purchase | 1,000 | $5.82 | $5,820 | 2,501 | Sep 19, 2023 |
| Foster Robert T | CEO and Director | Purchase | 1,600 | $5.60 | $8,960 | 50,470 | Sep 18, 2023 |
| Foster Robert T | CEO,CSO and Director | Purchase | 1,600 | $5.40 | $8,640 | 48,870 | Sep 15, 2023 |
| Foster Robert T | CEO and Director | Purchase | 20,000 | $2.00 | $40,000 | 45,259 | Feb 18, 2021 |
| Cavan John T | Chief Financial Officer | Purchase | 10,000 | $2.00 | $20,000 | 14,800 | Feb 18, 2021 |
| Wijngaard Peter | — | Purchase | 10,000 | $2.20 | $22,000 | 30,000 | Feb 16, 2021 |
| Wijngaard Peter | — | Purchase | 20,000 | $1.91 | $38,200 | 20,000 | Dec 18, 2020 |
| Foster Robert T | CEO and Director | Purchase | 25,000 | $1.58 | $39,500 | 25,259 | Dec 8, 2020 |
| BRANCACCIO JOHN P | — | Purchase | 7,000 | $1.53 | $10,710 | 7,008 | Dec 2, 2020 |
| JACOB GARY S | — | Purchase | 12,000 | $1.66 | $19,920 | 12,059 | Dec 1, 2020 |
| Cavan John T | Chief Financial Officer | Purchase | 4,500 | $1.62 | $7,290 | 4,800 | Nov 25, 2020 |
| Cavan John T | CFO | Award / Grant | 101,221 | — | — | 167,947 | Jan 3, 2018 |
| SAPIRSTEIN JAMES | Chief Executive Officer | Award / Grant | 322,092 | — | — | 492,819 | Jan 3, 2018 |
| Foster Robert T | Chief Scientific Officer | Award / Grant | 100,654 | — | — | 144,736 | Jan 3, 2018 |
| Cavan John T | CFO | Award / Grant | 46,726 | — | — | 66,726 | Jul 6, 2017 |
| SAPIRSTEIN JAMES | Chief Executive Officer | Award / Grant | 141,061 | — | — | 170,727 | Jul 6, 2017 |
| Sullivan-Bolyai John Z | Chief Medical Officer | Award / Grant | 58,681 | — | — | 58,681 | Jul 6, 2017 |
| Foster Robert T | Chief Scientific Officer | Award / Grant | 44,082 | — | — | 44,082 | Jul 6, 2017 |
| Cavan John T | CFO | Purchase | 20,000 | $0.65 | $13,000 | 20,000 | Jun 20, 2017 |
| SAPIRSTEIN JAMES | Chief Executive Officer | Option Exercise | 16,666 | $1.50 | $24,999 | 29,666 | Oct 27, 2016 |
| SAPIRSTEIN JAMES | Chief Executive Officer | Purchase | 10,000 | $1.00 | $10,000 | 13,000 | Feb 18, 2016 |
| SAPIRSTEIN JAMES | Chief Executive Officer | Purchase | 500 | $2.15 | $1,075 | 3,000 | Nov 30, 2015 |
| SAPIRSTEIN JAMES | Chief Executive Officer | Purchase | 2,500 | $1.64 | $4,100 | 2,500 | Nov 23, 2015 |
| BRANCACCIO JOHN P | — | Purchase | 4,393 | $1.49 | $6,546 | 6,408 | Mar 4, 2014 |
| SYNERGY PHARMACEUTICALS, INC. | — | Other | 9,000,000 | — | — | — | Feb 18, 2014 |
| BRANCACCIO JOHN P | — | Other | 2,015 | — | — | 2,015 | Feb 18, 2014 |
| JACOB GARY S | CEO and President | Other | 32,935 | — | — | 32,935 | Feb 18, 2014 |
| Denoyer Bernard | Chief Financial Officer | Other | 1,030 | — | — | 1,030 | Feb 18, 2014 |